• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Singular Genomics Systems Inc.

    4/18/24 4:31:13 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $OMIC alert in real time by email
    DEFA14A 1 omic_defa14a_fy24_proxy_.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934 (Amendment No. )

    Filed by the Registrant ☒

     

    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material under §240.14a‑12

     

    Singular Genomics Systems, Inc.

    (Name of Registrant as Specified in Its Charter)
     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
     

    Payment of Filing Fee (Check the appropriate box):

    ☒

    No fee required.

    ☐

    Fee computed on table below per Exchange Act Rules 14a‑6(i)(1) and 0‑11.

    ☐

    Fee paid previously with preliminary materials.

    ☐

    Fee paid computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     


     

    img193086711_0.jpg 


    img193086711_1.jpg 

    styleINAstyleINA Scan QR for digital voting P.O. BOX 8016, CARY, NC 27512-9903 Your vote matters! Singular Genomics Systems, Inc. Annual Meeting of Stockholders Wednesday, May 29, 2024 12:00 PM, Pacific Time Annual Meeting to be held virtually via the Internet - please visit www.proxydocs.com/OMIC for further details. Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report on Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On May 29, 2024 For Stockholders of record as of April 1, 2024 To order paper materials, use one of the following methods. For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/OMIC To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 17, 2024. Internet: www.investorelections.com/OMIC Call: 1-866-648-8133 Email: [email protected] * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. SEE REVERSE FOR FULL AGENDA Copyright © 2024 BetaNXT, Inc. or its affiliates. All Rights Reserved Singular Genomics Systems, Inc. Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1, 2 AND 3 PROPOSAL 1. To elect three Class III directors to serve until the 2027 annual meeting of stockholders or until their respective successors have been elected or appointed. 1.01 Andrew Spaventa 1.02 Marcia Eisenberg, Ph.D. 1.03 Michael Pellini, M.D. 2. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2024. 3. To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to effect, at the option of our Board of Directors, a reverse stock split of our common stock at a ratio between 1-for-10 to 1-for-30, inclusive, as determined by our Board of Directors in its sole discretion. We refer to this as the "Reverse Stock Split Proposal" or "Proposal 3." 4. To conduct any other business properly brought before the meeting or any adjournment thereof.


    Get the next $OMIC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OMIC

    DatePrice TargetRatingAnalyst
    8/17/2022$10.00 → $4.50Buy → Neutral
    UBS
    8/10/2022$3.50Buy → Neutral
    Goldman
    8/10/2022$3.00Buy → Underperform
    BofA Securities
    1/7/2022$21.00Neutral → Buy
    BofA Securities
    10/15/2021Outperform
    Cowen
    More analyst ratings

    $OMIC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Singular Highlights Key G4X™ Launch Milestones and Showcases Groundbreaking 3D Spatial Multiomic Performance at AGBT

    SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc., an innovator in high-throughput spatial multiomics technologies designed to advance precision medicine, today announced key development milestones for its G4X™ Spatial Sequencer at the Advances in Genome Biology and Technology (AGBT) conference in Marco Island, Florida. G4X Early Access Program Ongoing and Broader Availability on Track The G4X Early Access Program is currently underway at Beth Israel Deaconess Medical Center and Vanderbilt University Medical Center, providing valuable feedback highlighting the platform's real-world potential. "As the first early access site, we've had the chance to

    2/24/25 8:00:00 AM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Singular Genomics Announces Closing of Acquisition by Deerfield Management

    SAN DIEGO, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced today the closing of its acquisition by an affiliate of Deerfield Management Company, L.P.    On December 23, 2024, Singular Genomics announced that Deerfield had signed a definitive agreement to acquire all of the outstanding shares of Singular Genomics common stock not currently owned by Deerfield for $20.00 per share in cash. Following the satisfaction of customary conditions, including a vote of the holders of Singular Genomics' common stock to approv

    2/21/25 9:56:26 AM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Singular Genomics Enters into Agreement to be Acquired by Deerfield for $20.00 in Cash per Share

    SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC) ("Singular Genomics" or the "Company"), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it has entered into a definitive merger agreement whereby an affiliate of Deerfield Management Company, L.P. will acquire Singular Genomics in an all-cash transaction for $20.00 per share. The $20.00 per share represents 254% premium to the last closing share price for Singular's common stock prior to the September 12, 2024 public disclosure of Deerfield's initial acquisition proposal. The Singular Genomic

    12/23/24 8:30:00 AM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $OMIC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tang Kevin bought $1,806,220 worth of shares (122,416 units at $14.75) (SEC Form 4)

    4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

    9/18/24 4:31:08 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Spaventa Andrew bought $49,612 worth of shares (118,468 units at $0.42) (SEC Form 4)

    4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

    11/20/23 4:31:38 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Glezer Eli N. bought $85,640 worth of shares (200,000 units at $0.43), increasing direct ownership by 5% to 4,570,000 units (SEC Form 4)

    4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

    11/20/23 4:30:55 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $OMIC
    SEC Filings

    View All

    Singular Genomics Systems Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Material Modification to Rights of Security Holders, Changes in Control of Registrant

    8-K - Singular Genomics Systems, Inc. (0001850906) (Filer)

    2/27/25 1:42:39 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SCHEDULE 13D/A filed by Singular Genomics Systems Inc.

    SCHEDULE 13D/A - Singular Genomics Systems, Inc. (0001850906) (Subject)

    2/25/25 9:18:06 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form EFFECT filed by Singular Genomics Systems Inc.

    EFFECT - Singular Genomics Systems, Inc. (0001850906) (Filer)

    2/24/25 12:15:05 AM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $OMIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tang Kevin returned 372,000 shares to the company (SEC Form 4)

    4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

    2/27/25 8:54:47 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Executive Officer Spaventa Andrew returned 143,310 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

    2/25/25 8:12:58 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Financial Officer Meeter Dalen returned 9,502 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

    2/25/25 8:11:40 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $OMIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Singular Genomics Systems downgraded by UBS with a new price target

    UBS downgraded Singular Genomics Systems from Buy to Neutral and set a new price target of $4.50 from $10.00 previously

    8/17/22 9:15:00 AM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Singular Genomics Systems downgraded by Goldman with a new price target

    Goldman downgraded Singular Genomics Systems from Buy to Neutral and set a new price target of $3.50

    8/10/22 6:31:06 AM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Singular Genomics Systems downgraded by BofA Securities with a new price target

    BofA Securities downgraded Singular Genomics Systems from Buy to Underperform and set a new price target of $3.00

    8/10/22 6:30:40 AM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $OMIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Singular Genomics Systems Inc.

    SC 13D/A - Singular Genomics Systems, Inc. (0001850906) (Subject)

    11/22/24 7:55:51 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13D filed by Singular Genomics Systems Inc.

    SC 13D - Singular Genomics Systems, Inc. (0001850906) (Subject)

    11/5/24 7:29:21 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13D/A filed by Singular Genomics Systems Inc.

    SC 13D/A - Singular Genomics Systems, Inc. (0001850906) (Subject)

    11/1/24 7:54:29 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $OMIC
    Leadership Updates

    Live Leadership Updates

    View All

    Singular Genomics Appoints Genomics Veteran Marcia Eisenberg, Ph.D., to Board of Directors

    SAN DIEGO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the appointment of Marcia Eisenberg, Ph.D., to the Company's Board of Directors. Dr. Eisenberg currently serves as Senior Vice President and Enterprise Chief Scientific Officer at Labcorp (NYSE:LH) and brings more than 30 years of experience with molecular genetics, DNA testing, biotechnology, and molecular oncology. "Marcia's deep and diverse genomics expertise will be an asset to Singular as we drive our business strategy forward, and we are delighted to w

    8/8/23 4:05:00 PM ET
    $LH
    $OMIC
    Medical Specialities
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Singular Genomics Appoints Sam Ropp, Ph.D., as Chief Commercial Officer

    SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the appointment of Sam Ropp, Ph.D., as Chief Commercial Officer. In this role, Dr. Ropp will oversee the company's commercial function, including commercialization of the G4 Sequencing Platform. He will report to Drew Spaventa, Chief Executive Officer and Founder of Singular Genomics. The company also announced the appointment of Jeff Bullard as Head of Sales for North America. "As an accomplished life science leader, Sam brings the deep knowledge and experi

    8/2/22 7:30:00 AM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Singular Genomics Appoints Genomics Research Pioneer Elaine R. Mardis, Ph.D., to Board of Directors

    LA JOLLA, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the addition of Elaine R. Mardis, Ph.D., to the Company's Board of Directors. Dr. Mardis is a pioneering researcher internationally recognized in cancer genomics with a focus on the application of genomic technologies to improve the understanding of human disease and the precision of medical diagnosis, prognosis and treatment. "We are thrilled to have Elaine join the Board of Directors. She brings the rare combination of world-class scientific, indust

    1/6/22 4:05:00 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $OMIC
    Financials

    Live finance-specific insights

    View All

    Singular Genomics Reports Recent Updates and Third Quarter 2024 Financial Results

    SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the third quarter ended September 30, 2024. "In the third quarter, we made significant progress in the development of the G4X spatial sequencer," said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics. "We are encouraged by the interest in the G4X and validation received through the expansion of our Spatial Technology Access Services project funnel, which reinfo

    11/12/24 4:05:00 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Singular Genomics Reports Recent Highlights and Second Quarter 2024 Financial Results

    SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the second quarter ended June 30, 2024. "It was another busy and productive quarter for our team as we progressed development of the G4X Spatial Sequencer while supporting our G4 customers," said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics. "The early interest in our Spatial Technology Access Services is an encouraging sign that the unique capabilities and

    8/13/24 4:05:00 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Singular Genomics to Report Second Quarter 2024 Financial Results on August 13, 2024

    SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the second quarter ended June 30, 2024 after the market close on Tuesday, August 13, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing 1-888-506-0062 for domestic callers or 1-973-528-0011 for international callers and using conference ID 66

    7/30/24 5:05:42 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials